KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Gross Margin (2016 - 2023)

TherapeuticsMD filings provide 13 years of Gross Margin readings, the most recent being 100.0% for Q4 2023.

  • On a quarterly basis, Gross Margin changed 0.0% to 100.0% in Q4 2023 year-over-year; TTM through Dec 2023 was 92.47%, a 2622.0% decrease, with the full-year FY2023 number at 100.0%, up 200.0% from a year prior.
  • Gross Margin hit 100.0% in Q4 2023 for TherapeuticsMD, up from 100.0% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 2082.45% in Q1 2022 to a low of 100.0% in Q3 2023.
  • Median Gross Margin over the past 5 years was 81.28% (2019), compared with a mean of 184.76%.
  • Biggest five-year swings in Gross Margin: surged 200604bps in 2022 and later tumbled -198245bps in 2023.
  • TherapeuticsMD's Gross Margin stood at 81.9% in 2019, then dropped by -8bps to 75.28% in 2020, then decreased by -1bps to 74.64% in 2021, then skyrocketed by 34bps to 100.0% in 2022, then changed by 0bps to 100.0% in 2023.
  • The last three reported values for Gross Margin were 100.0% (Q4 2023), 100.0% (Q3 2023), and 100.0% (Q2 2023) per Business Quant data.